Aurobindo Pharma Sets ₹800 Cr Buyback at ₹1,475 Price; Record Date 17 April 2026

Aurobindo Pharma’s board approved a share buyback of up to ₹800 crore on 6 April 2026. A share buyback occurs when a business repurchases its own shares from investors in exchange for cash, generally at a set price.

The company has set the buyback price at ₹1,475 per share. This is about 10% higher than the current Aurobindo Pharma share price, which is around ₹1,335 as of 6 April 2026 (10.55 AM).

The record date for identifying eligible stockholders is set for 17 April 2026.

What Are The Specifics Of The Buyback?

The company plans to buy back up to 5,423,728 equity shares. This represents about 0.93% of its total equity share capital.

The total size of the buyback is ₹800 crore. This accounts for:

Around 3.93% of the standalone paid-up capital and free reserves

Around 2.62% on a consolidated basis

The entire process will be conducted through the tender offer route. This means shareholders can offer their shares back to the company in proportion to their holdings.

It's also important to keep in mind that the total buyback value does not include other expenses like taxes, broking, regulatory fees, and other related expenditures.

What Is The Timeline And Who Is Eligible?

The record date determines eligibility. Only those shareholders who hold shares of Aurobindo Pharma as of 17 April 2026 will be able to participate in the buyback.

The offer is open to all shareholders, including promoters. Shares will be accepted in proportion to what each investor holds, in line with the rules.

The company said the buyback will follow existing regulations under the SEBI buyback framework and the Companies Act. These rules lay down how such offers are carried out.

After the record date, shareholders who are eligible will get the necessary details. This includes the process and timeline for submitting shares under the tender route.

Also Read - Brent Oil Reaches US$141, Its Highest Level Since The 2008 Financial Crisis

What Do The Latest Numbers Say About The Company?

The buyback comes at a time when the company has reported stable numbers.

For Q3FY26, Aurobindo Pharma posted a net profit of ₹910 crore. This is about 8% higher than the same period last year. Revenue for the quarter stood at ₹8,646 crore, compared to ₹7,979 crore a year ago.

The buyback price is higher than the current market price, which could support investor interest, though participation will depend on individual holdings and acceptance levels.

Sources:

Mint

Business Standard